NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sirius Therapeutics, Inc.

Sirius Therapeutics, Inc.

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://www.siriusrna.com/

Last Round

Series B

Extension

May 9, 2025

Est. Valuation

$253M

Total Funding Raised

$207.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Sirius Therapeutics, Inc. is a biotechnology company developing innovative siRNA therapies for global markets, focusing on cardiovascular and chronic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA interferenceRNAigene silencingbiotechnologydrug delivery platformclinical-stage biotechsiRNA therapeuticschronic disease treatmentdrug discoverybiopharmaRNA medicinetherapeutic pipelineclinical developmentgene therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sirius Therapeutics, Inc. Comparables

Compare Sirius Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Sirius Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ADARx Pharmaceuticals
86%
Argo Biopharma
84%
Rona Therapeutics
83%

Sirius Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 9, 2025
Series BOct 9, 2023
Series BSep 1, 2023
Series AJul 13, 2022

Key People

Founding team and executive leadership

Hailei Lu

Chief Financial Officer

Executive Team

Sirius Therapeutics, Inc. Investors

Notable investors and investment history

Sirius Therapeutics, Inc. investors
InvestorRounds
BioTrack CapitalSeries B Extension
Creacion VenturesSeries B, Series B Extension, Series A
OrbiMedSeries B, Series B Extension, Series A
Hankang CapitalSeries B Extension, Series B
Delos Capital PartnersSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2026

    Grew 29% QoQ, from 14 to 18 employees.

  • Apr 27, 2026

    Grew 38% QoQ, from 13 to 18 employees.

Sirius Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sirius Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sirius Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range19
Year Founded2021
Last FundingMay 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.